Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer

University Hospital, Strasbourg, France130 enrolled

Overview

Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage. Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.

Study Type

OBSERVATIONAL

Enrollment

130

Conditions

Ovarian Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient (≥18 years old) * Operated on at the HUS between January 1, 2010 and December 31, 2022 * Having undergone primary or interval cytoreductive surgery * Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin Exclusion Criteria: * Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques. * Autres types histologiques de cancer de l'ovaire * Stades de la maladie FIGO I, II, IIIA et IIIC * Chirurgie de clôture.

Locations (1)

Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Study of progression-free survival at 36 months

Time frame: At 36 months

Central Contacts

Lise LECOINTRE, MD

CONTACT

33 3 88 12 75 10 lise.lecointre@chu-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.